US Insurance Giant Aetna Agrees to $117.7M Settlement Over Medicare Advantage Fraud Claims

Aetna Inc., a major US health insurer and subsidiary of CVS Health, has agreed to pay $117.7 million (£88.7 million) to resolve allegations that it violated federal fraud laws by submitting inaccurate diagnosis codes to inflate its payments from the Medicare Advantage programme.

The settlement, announced by the US Department of Justice on Wednesday, brings to a close claims that the insurer made false and misleading submissions to federal healthcare authorities over several years.

Settlement Resolves False Claims Act Allegations

Under the terms of the settlement, Aetna will pay $117.7 million (£88.7 million) to resolve allegations brought under the False Claims Act, a federal law that allows the government to pursue civil penalties when entities knowingly submit false claims for government funds.

In an official statement, the Justice Department said Aetna submitted inaccurate and untruthful diagnosis data to the Centers for Medicare & Medicaid Services (CMS) in order to inflate the risk‑adjusted payments it received for Medicare Advantage Plan enrollees. CMS administers the Medicare Advantage programme, which pays private insurers more for beneficiaries expected to have higher healthcare costs.

The complaint alleged that Aetna failed to delete or withdraw inaccurate diagnosis codes after chart reviews revealed they were unsupported by medical records, as required to ensure payments were based on accurate clinical information.

It further alleged that between 2018 and 2023, Aetna knowingly submitted or failed to correct inaccurate codes for morbid obesity, including instances where patients' Body Mass Index (BMI) did not support such diagnoses.

Government Statements on Enforcement

Assistant Attorney General Brett A. Shumate of the Justice Department's Civil Division highlighted the importance of accountability in healthcare reimbursement. 'The government pays private insurers over $530 billion (£399.41 billion) each year to care for Americans enrolled in Medicare Advantage,' Shumate said in a statement. 'We will continue to hold accountable insurers that knowingly submit inaccurate or unsupported diagnoses to improperly inflate reimbursement.'

The Justice Department emphasised that the settlement reflects a coordinated effort between its Civil Division, the Fraud Section, and the US Attorney's Office for the Eastern District of Pennsylvania, alongside investigatory support from the US Department of Health and Human Services Office of Inspector General (HHS‑OIG).

Despite agreeing to the settlement, Aetna and its parent company CVS Health issued statements denying the underlying allegations. A spokesman said the settlement should not be construed as an admission of liability, noting that the insurer chose to resolve the matter to avoid continuing the uncertainty and expense of protracted litigation.

Whistleblower Share Underlines Case Origins

The settlement stems from a qui tam lawsuit filed under the False Claims Act, which allows private individuals to sue on the government's behalf and share a portion of any recovery.

The qui tam case was brought by a former Aetna risk‑adjustment coding auditor, Mary Melette Thomas, who will receive $2,012,500 (£1,516,624) from the settlement as her share under whistleblower provisions.

Whistleblower suits are significant tools in the government's enforcement arsenal, often revealing systemic issues that might otherwise remain undisclosed. Under the False Claims Act, whistleblowers provide crucial tips and evidence that help prosecuting authorities pursue complex fraud cases against large corporations.

Broader Scrutiny of Medicare Advantage Practices

The Aetna settlement reflects wider federal scrutiny of how private insurers handle Medicare Advantage risk‑adjustment coding, a process that directly affects the level of payments received from the CMS.

Inaccurate or unsubstantiated coding has been a focus in multiple enforcement actions, as regulators work to ensure that government funds are distributed on the basis of legitimate patient health needs.

Other insurers and healthcare organisations have faced similar allegations in recent years, with federal authorities pursuing cases over unsupported diagnosis codes and improper billing practices. These actions underscore ongoing efforts to safeguard the integrity of taxpayer‑funded healthcare programmes that cover millions of Americans.

Implications for the Healthcare Industry

The settlement with Aetna underscores the importance of compliance and accurate reporting in the Medicare Advantage system. As private insurers administer plans for seniors and other beneficiaries, federal enforcement continues to stress that mistakes or misconduct in coding and reporting can carry significant financial consequences, even for well‑established industry players.

For Aetna, the resolution closes a chapter in a legal dispute centred on diagnostic coding practices but leaves unanswered questions about how risk‑adjustment strategies are managed across the industry.

By resolving the case, Aetna and CVS Health can now redirect focus to their core operations while navigating the heightened regulatory landscape that surrounds US federal healthcare programmes.